Dear Friends and Colleagues,
Today -- November 19, 2022 -- we mourn the passing of Mitchell Rosenthal, MD, the founder of Phoenix House, the largest private, non-profit therapeutic drug-treatment program in the United States, and a founding medical advisory board member of Fisher Wallace Labs.
He was a constant and thoughtful advisor to the company over the past fifteen years, on many levels, and was instrumental in introducing us to key opinion leaders in the psychiatric and addiction communities.
Mitch believed in our work and the potential of our medical device and arranged to have it used in a remarkable study of 392 patients at Phoenix House in 2009, which showed that with only a modest number of treatments, our device could markedly improve rehab retention (by managing mood and sleep in the first 90 days of residential treatment).
I had the pleasure and honor of serving on the board of the Rosenthal Center, which in his latter years was Mitch’s drug policy non-profit that led the way in creating a dialogue about the importance of the expansion of treatment programs nationwide.
He was a dear and cherished friend and will be missed by so many whose lives he touched.
I hope you will take a moment to read his obituary which appeared this past weekend in the New York Times:
Dr. Mitchell Rosenthal, Phoenix House Founder, Dies at 87 - The New York Times
Fisher Wallace Labs